{"schema_version":"secwatch.filing_event.v1","accession":"0001453687-26-000063","form_type":"8-K","ticker":"RNAC","cik":"0001453687","company_name":"Cartesian Therapeutics, Inc.","filed_at":"2026-03-09T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.112905+00:00","generated_at":"2026-05-15T17:37:18.156476+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.7,"confidence":"high","headline":"Cartesian Therapeutics reports FY2025 net loss of $130.3M; cash $126.9M funds into mid-2027","bullets":["Net loss of $130.3M ($5.02 per basic share) compared to $77.4M ($4.48) in FY2024.","R&D expenses rose to $58.0M from $45.1M, driven by Phase 3 AURORA trial and headcount growth.","Cash, equivalents and restricted cash of $126.9M expected to support operations into mid-2027, including AURORA completion.","Phase 3 AURORA trial for Descartes-08 in myasthenia gravis on track to enroll ~100 patients; Phase 2 TRITON in myositis IND accepted, initiation expected 1H26.","Board changes: Adrian Bot appointed in Dec 2025; Carsten Brunn named Chairman in Oct 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001453687-26-000063","json":"https://secwatch.observer/filing/0001453687-26-000063.json","markdown":"https://secwatch.observer/filing/0001453687-26-000063.md","text":"https://secwatch.observer/filing/0001453687-26-000063.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1453687/000145368726000063/0001453687-26-000063-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1453687/000145368726000063/rnac-20260309.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T17:37:18.156476+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}